On August 20, 2025, in Shanghai, China, 3D Medicines and Canton Biologics officially signed a strategic cooperation agreement. According to the agreement, the two parties will deepen their collaboration in areas such as targeted lipid nanoparticle (tLNP) delivery, tumor vaccines, and in vivo CAR-T/NK therapies. This collaboration will leverage 3D Medicines' self-developed, proprietary AI+mRNA R&D platform and liposome delivery system (3D-LNP), combined with Canton Biologics' expertise and scale in mRNA manufacturing. The specific implementation will follow subsequent formal agreements. This partnership signifies that 3D Medicines is accelerating its expansion into mRNA research, securing manufacturing capacity to support the subsequent clinical development and future commercialization of innovative therapy products based on mRNA-LNP technology.

3D Medicines has established a globally proprietary mRNA technology platform and LNP delivery system platform. The mRNA technology platform is a multi-modular tumor vaccine analysis platform (3D-PreciseAg) built on advanced AI technology, capable of supporting massive antigen multi-omics analysis and selecting optimal tumor antigens. It also possesses a proprietary AI-enhanced LNP delivery technology platform. Using AI intelligent algorithms to screen thousands of compounds, it can ultimately synthesize various LNP products suitable for different delivery scenarios. This aims to improve the delivery efficiency and targeting of drugs such as mRNA tumor vaccines and in vivo CAR-T/NK immune cell therapies, while also significantly reducing toxicity.

Canton Biologics' one-stop advanced therapy CRDMO platform covers the entire workflow from GMP-grade DNA template preparation, in vitro transcribed RNA synthesis, LNP delivery system development and production, to final product formulation and filling. Its process validation and quality systems meet FDA/EMA/NMPA submission guidelines, and its Suzhou base has passed a European Union QP audit. This enables Canton Biologics to deliver products compliant with both Chinese and US regulatory requirements for multiple innovative pipelines of 3D Medicines based on mRNA-LNP technology, ensuring smooth clinical advancement and commercial realization.

This cooperation achieves a perfect fit, from source innovation to industrialization. It is believed that the deep integration of the complementary strengths of both parties will accelerate the industrialization process of advanced therapies, injecting sustained innovative momentum and long-term value into the industry.